{"id":4923,"date":"2019-04-30T16:59:05","date_gmt":"2019-04-30T11:29:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4923"},"modified":"2021-07-24T12:57:19","modified_gmt":"2021-07-24T07:27:19","slug":"notizia-praluent","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d314fd1cfd9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d314fd1cfd9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-praluent\/#A_Praluent_boost_for_Sanofi_and_Regeneron\" >A Praluent boost for Sanofi, and Regeneron<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-praluent\/#EU_grants_Marketing_Authorization_to_Zynquista\" >EU grants Marketing Authorization to Zynquista<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-praluent\/#Novo_Nordisks_drug_proves_to_be_beneficial_in_cutting_blood_sugar\" >Novo Nordisk\u2019s drug\nproves to be beneficial in cutting blood sugar<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-praluent\/#Pfizers_Talzenna_steals_the_show\" >Pfizer\u2019s Talzenna\nsteals the show<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_Praluent_boost_for_Sanofi_and_Regeneron\"><\/span><strong>A Praluent boost for Sanofi, and Regeneron<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The U.S. FDA has given its nod to <strong>Praluent<\/strong> (alirocumab) to be used for reducing the risk of <strong>heart attack, <a href=\"https:\/\/www.delveinsight.com\/report-store\/ischemic-stroke-market\">stroke<\/a>,<\/strong> and unstable angina requiring hospitalization in adults with established<strong> cardiovascular (CV) disease<\/strong>. Praluent is an injectable prescription medicine co-developed by <strong>Sanofi<\/strong> and <strong>Regeneron<\/strong> Pharmaceuticals. It is a similar label extension as that of <strong>Amgen&#8217;s<\/strong> drug, <strong>Repatha<\/strong>, which was approved in December 2017.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"EU_grants_Marketing_Authorization_to_Zynquista\"><\/span><strong>EU grants Marketing Authorization to Zynquista <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The European Commission has given an OK to <strong>Sanofi\u2019s<\/strong> \u2018<strong>Zynquista\u2019<\/strong> (sotagliflozin) for the treatment of adults suffering from type 1 diabetes. Developed jointly with a US firm <strong>Lexicon Pharmaceuticals, <\/strong>this is the first ever approved noninsulin therapy in the EU. Zynquista is once-daily doses of 200 mg and 400 mg, as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 <strong>diabetes (T1D) mellitus<\/strong>. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novo_Nordisks_drug_proves_to_be_beneficial_in_cutting_blood_sugar\"><\/span><strong>Novo Nordisk\u2019s drug\nproves to be beneficial in cutting blood sugar <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">A major diabetes-drug of Novo Nordisk, <strong>Victoza, <\/strong>showed successful results in reducing blood sugar level in children with <strong>Type 2 diabetes<\/strong>. The clinical trials showed that <strong>Victoza injection <\/strong>is a safer, and efficient treatment option for pediatric patients. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pfizers_Talzenna_steals_the_show\"><\/span><strong>Pfizer\u2019s Talzenna\nsteals the show <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">Pfizer\u2019s PARP inhibitor, <strong>Talzenna<\/strong> (talazoparib) received positive feedback from the <strong>Committee for Medicinal Products for Human Use <\/strong>(CHMP) of the European Medicines Agency (EMA). Talzenna is used for the treatment of adults with <strong>mutations in germline breast cancer susceptibility gene (gBRCA)1\/2<\/strong>. Including Talzenna there are other thirteen drugs which got approval from the committee like Novo Nordisk\u2019s <strong>Esperoct<\/strong> (turoctocog alfa pegol) and <strong>Alexion\u2019s<\/strong> Ultomiris (ravulizumab). <\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Praluent boost for Sanofi, and Regeneron The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. Praluent is an injectable prescription medicine co-developed by Sanofi and Regeneron Pharmaceuticals. It is a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4924,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[812,877,460,1511,504,533],"industry":[17225],"therapeutic_areas":[17242,17240],"class_list":["post-4923","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-diabetes","tag-novo-nordisk","tag-pfizer","tag-praluent","tag-regeneron","tag-sanofi","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 30\/04\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-praluent\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 30\/04\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-praluent\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-30T11:29:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/04164410\/NOTIZIA-PRAULENT.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 30\/04\/2019 - DelveInsight Business Research","description":"The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent","og_locale":"en_US","og_type":"article","og_title":"Notizia 30\/04\/2019 - DelveInsight Business Research","og_description":"The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-30T11:29:05+00:00","article_modified_time":"2021-07-24T07:27:19+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/04164410\/NOTIZIA-PRAULENT.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent","url":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent","name":"Notizia 30\/04\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/04164410\/NOTIZIA-PRAULENT.png","datePublished":"2019-04-30T11:29:05+00:00","dateModified":"2021-07-24T07:27:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-praluent"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-praluent#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/04164410\/NOTIZIA-PRAULENT.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/04164410\/NOTIZIA-PRAULENT.png","width":647,"height":345,"caption":"NOTIZIA"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/04164410\/NOTIZIA-PRAULENT-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Praluent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Praluent<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 30, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 30, 2019 4:59 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"NOTIZIA ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4923"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4923\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4924"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4923"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4923"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}